Since the COVID-19 pandemic hit, things haven’t been all bad—at least, not from the perspective of a major R&D player like Genentech.
“There’s an enormous number of silver linings” that have come out of the pandemic, CEO Alexander Hardy said during an interview that aired Monday as part of Fierce JPM Week.
One major bright spot? Faster, more plentiful partnerships—both public-private, but also private-private. “I think partnerships have really come into achieving their potential,” Hardy said.